Skip to main content

Clinical Trial Search Results

Clinical Trial Search Results

Showing 46-54 out of 281 results.
NCT05281471

A Randomized Phase 3 Study Assessing the Efficacy and Safety
of Olvi-Vec followed by Platinum-doublet Chemotherapy and
Bevacizumab Compared with Platinum-doublet Chemotherapy and
Bevacizumab in Women with Platinum-Resistant/Refractory
Ovarian Cancer (OnPrime Study

Icon for trial | OLVI-VEC-022 A Randomized Phase 3 Study Assessing the Efficacy and Safety 
of Olvi-Vec followed by Platinum-doublet Chemotherapy and 
Bevacizumab Compared with Platinum-doublet Chemotherapy and 
Bevacizumab in Women with Platinum-Resistant/Refractory 
Ova

This study is currently enrolling.

You are invited to take part in a research study. This research study is studying Olvi-Vec as a possible treatment for platinum-resistant or platinum-refractory ovarian cancer including fallopian tube cancer and peritoneal carc ...

NCT04793958

A Randomized PHase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

Icon for trial | 849-010 A Randomized PHase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

This study is currently enrolling.

This is a study involving an investigational (experimental) drug called MRTX849, being developed by Mirati Therapeutics, Inc., which is the company that provides MRTX849 study drug and is funding and organizing the study. Inves ...

NCT05147220

A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib

Icon for trial | CLOU064C12302 A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrut

This study is currently enrolling.

The main purpose of the study is to find out if patients treated with remibrutinib may experience fewer MS relapses (also called clinical attacks, exacerbations or flare ups) than patients treated with teriflunomide (also known ...

NCT05219617

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF CARISBAMATE (YKP509) AS ADJUNCTIVE TREATMENT FOR SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME IN CHILDREN AND ADULTS,
WITH OPTIONALOPEN-LABEL EXTENSION

Icon for trial | YKP509C003 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF CARISBAMATE (YKP509) AS ADJUNCTIVE TREATMENT FOR SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME IN CHILDREN AND ADULTS, 
WITH OPTIONALOPEN-LABEL EX

This study is currently enrolling.

Participants will be asked to join this study because they have Lennox-Gastaut Syndrome (LGS), a rare type of epilepsy that results in abnormal brain activity and seizures. It usually starts at an early age and causes seizures ...

NCT05206773

A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults with Fabry Disease who are Treatment-naïve or Untreated for
At least 6 Months

Icon for trial | EFC17045 A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults with Fabry Disease who are Treatment-naïve or Untreated for
At least 6 Mo

This study is currently enrolling.

The purpose of the study is to evaluate daily oral doses of the study drug called venglustat compared to placebo: what is the effectiveness (how well it works) on symptoms of the Fabry disease, mainly neuropathic pain and abdom ...

NCT04161885

A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T)

Icon for trial | M19-063 A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T)

This study is currently enrolling.

The purpose of this study is to evaluate the safety and efficacy of study drugs venetoclax and azacitidine compared to Best Supportive Care (no study medication) when given as maintenance therapy after allogeneic stem cell tran ...